Japan iPS position looks strong despite Bayer filing
This article was originally published in Scrip
New information on a local patent filed by a major international pharmaceutical company on induced pluripotent stem (iPS) cell production methods has created a stir in Japan because of its relation to high-profile academic and state-supported programmes in the field.
You may also be interested in...
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.